close
close

Lonza prices EUR 1.2 billion dual-tranche straight bonds

Lonza prices EUR 1.2 billion dual-tranche straight bonds

Lonza Group AG / Keywords: Bond

Lonza prices EUR 1.2 billion dual-tranche straight bonds

Basel, Switzerland, August 28, 2024 – Lonza Finance International NV, a wholly owned subsidiary of Lonza Group Ltd, Basel (“Lonza”), today announced the pricing of its dual tranche EUR 1.2 billion straight bonds. The bonds have maturities of six and ten years and coupons of 3.25% and 3.50% respectively.

The issuer is Lonza Finance International NV and the bonds are guaranteed by Lonza. Lonza will apply for the listing of the bonds on the Luxembourg Stock Exchange (Regulated Market). The proceeds of the bonds will be used for general corporate purposes, including the financing of acquisitions and the refinancing of existing debt.

Lonza’s issuer rating is currently BBB+ (S&P Global Ratings) with a stable outlook.

A consortium consisting of BofA, Citibank, HSBC, JP Morgan and UBS was instructed to place the bond as Joint Active Bookrunners.

Key data

Six-year tranche

Ten-year tranche

Issue size

600 million euros

600 million euros

Expected payment date

September 4, 2024

September 4, 2024

Adulthood

September 4, 2030

September 4, 2034

Issue price

99.448 percent

98.361 percent

Exchange price

100 percent

100 percent

Coupon

3.25 percent per year

3.50 percent per year

About Lonza

Lonza is one of the world’s largest healthcare manufacturing companies. Our global community of approximately 18,000 colleagues, spread across five continents, helps pharmaceutical, biotechnology and nutrition companies bring their therapies to market. United by our vision to bring every therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, enabling their patients to benefit from life-saving and life-enhancing treatments.

Our company is structured to meet the complex needs of our customers across four divisions: Biologics, Small Molecules, Cell & Gene and Capsules & Health Ingredients.Our company generated sales of CHF 3.1 billion with CORE BITDA of CHF 893 million in the first half of 2024. For more information, please visit www.lonza.com

Follow @Lonza on LinkedIn
Follow @LonzaGroup on X

Contact details Lonza

Victoria Morgan
Head of External Communications
Lonza Group BV

Phone +41 61 316 2283
(email address)

Daniel Buchta
Head of Investor Relations
Lonza Group BV
Phone +41 61 316 2985

(email address)

Additional information and disclaimer
Lonza Group Ltd is headquartered in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the continued listing requirements of the SGX-ST but remains subject to rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this press release may constitute forward-looking statements. These statements are based on Lonza Group Ltd’s current expectations and estimates, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainties and are qualified in their entirety. Actual results in the future may differ materially from the forward-looking statements contained in this press release due to a variety of factors. In addition, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update any statements contained in this press release.

All trademarks are owned by Lonza and are registered in CH, US and/or EU, or belong to their respective third party owners and are used for informational purposes only.

Privacy Policy link

To delete all data immediately